Published in Pharma Investments, Ventures and Law Weekly, June 12th, 2005
The report authored by James Kreuger, professor and medical director of Investigative Dermatology at Rockefeller University, and Bruce Miller, MD at Oregon Medical Research Center, presents both PASI (Psoriasis Area Severity Index) and patient biopsy results, respectively the primary and secondary endpoints of the trial.
Although the six injection, 20 week trial of Psoraxine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.